<DOC>
	<DOC>NCT00945334</DOC>
	<brief_summary>In this study the investigators aim to compare the efficacy of neomycin to a combination of rifaximin and neomycin in the treatment of C-IBS subjects with methane on their breath test. This study will be conducted in collaboration with Dr. John DiBaise at the Mayo Clinic in Scottsdale, AZ and Dr. Satish Rao in Georgia Regents University in Augusta, GA.</brief_summary>
	<brief_title>Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<mesh_term>Neomycin</mesh_term>
	<criteria>Rome III positive IBS subjects (1875 years of age) Meet criteria for constipation predominant IBS symptoms including ≤ 3 complete spontaneous bowel movements per week with hard or lumpy stools. Presence of detectable methane on single breath sample (≥ 3ppm). If subjects are ≥ 50 years old, a colonoscopy had to have been completed within the past 5 years. Subjects with history of intestinal surgery (except appendectomy or cholecystectomy) Recent antibiotic use (within the last 30 days) Subjects with known pelvic floor dysfunction Pregnancy Creatinine level &gt; 1.4 Poorly controlled/uncontrolled significant medical condition that would interfere with study procedures Subjects with hearing loss and/or tinnitus History of bowel obstruction History of celiac disease History of inflammatory bowel disease Cirrhosis Diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Constipation predominant Irritable Bowel Syndrome</keyword>
</DOC>